Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

- Stage IIIB (with confirmed malignant pleural effusion), stage IV, or recurrent
disease

- Mixed tumors categorized by the predominant cell type are allowed provided no
small cell elements exist

- Cytologic or histologic elements can be established on metastatic tumor
aspirates or biopsy

- Measurable disease as defined by RECIST criteria

- No squamous cell carcinoma (group 1)

- No history of brain metastases (group 1)

- History of treated brain metastases allowed provided patient is not taking
steroids and anti-seizure mediation (group 2)

PATIENT CHARACTERISTICS:

- ECOG performance status 0-1

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Bilirubin ≤ 1.5 mg/dL

- Creatinine ≤ 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 3 times ULN (≤ 5 times ULN with liver metastases)

- AST and ALT ≤ 3 times ULN (≤ 5 times ULN with liver metastases)

- INR < 1.5 or PTT normal (group 1)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during (groups 1 and 2) and for 6
months after completion of study treatment (group 1)

- No preexisting peripheral neuropathy ≥ grade 2

- Must be able to swallow tablets

- No cardiovascular condition, including any of the following:

- Myocardial infarction within the past 6 months

- Cerebrovascular ischemia or stroke within the past 6 months

- NYHA congestive heart failure > class II

- Unstable angina pectoris

- Serious cardiac arrhythmia requiring medication

- Significant vascular disease

- Symptomatic peripheral vascular disease

- No concurrent medical condition, psychiatric illness, or limitations that would limit
study compliance

- No ongoing active infection or ongoing fever within the past 6 months

- No history of uncontrolled hypertension, defined as blood pressure ≥ 150/90 mm Hg
despite being on a stable regimen of anti-hypertensive therapy

- No serious nonhealing wound, ulcer, or bone fracture within the past 4 weeks

- No ongoing or active infection

- No history of thrombotic or hemorrhagic disorders, bleeding diathesis, or
coagulopathy (group 1)

- No bleeding > grade 2 or any bleeding requiring intervention within the past 4 weeks
(group 1)

- No history of gross hemoptysis (defined as > ½ teaspoon of bright red blood) (group
1)

- Urine protein:creatinine (UPC) ratio < 1.0 by spot urinalysis

- For UPC ratio > 0.5, a 24-hour urine protein must be obtained and the urine
protein level must be < 1,000 mg (group 1)

- None of the following conditions (group 1):

- Grade II or greater peripheral vascular disease

- Abdominal fistula

- Gastrointestinal perforation

- Intra-abdominal abscess

- No known hypersensitivity to any component of bevacizumab (group 1)

- No history of hypertensive crisis or hypertensive encephalopathy (group 1)

PRIOR CONCURRENT THERAPY:

- More than 4 weeks since prior major surgical procedure

- More than 7 days since prior minor surgical procedure

- No prior chemotherapy for advanced NSCLC

- Postoperative adjuvant chemotherapy for previously resected NSCLC allowed if
last dose was given > 1 year ago

- More than 3 weeks since prior radiation therapy and recovered

- More than 3 weeks since prior immunotherapy and/or hormonal therapy (not including
hormone replacement therapy or contraceptives) and recovered

- More than 14 days since prior enzyme inducing anti-epileptic drugs (EIAEDs)

- More than 10 days since prior and no concurrent daily treatment with acetylsalicylic
acid (> 325 mg/day) or NSAIDs known to inhibit platelet function for chronic
conditions (group 1)

- No concurrent major surgical procedure (group 1)

- No concurrent carbamazepine, phenobarbital, or phenytoin

- No concurrent therapeutic anticoagulation (group 1)

- Prophylactic anticoagulation of venous access devices is allowed

- No concurrent treatment with dipyridamole, ticlopidine, clopidogrel, or cilostazol
(group 1)

- No concurrent combination antiretroviral therapy for HIV-positive patients